This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Stretta Procedure For GERD: Successful 10 Year Follow-Up Data Presented At Digestive Disease Week--Sustained Improvement, Long-Term Efficacy

ORLANDO, Fla., May 19, 2013 /PRNewswire/ -- The non-surgical Stretta® procedure employing low power and low temperature radiofrequency (RF) energy is effective in control of gastroesophageal reflux disease (GERD), and eliminates or reduces the need for medication 10 years post-procedure, according to an independent, prospective long-term assessment presented today at the Digestive Disease Week (DDW) meeting May 18-21, 2013 in Orlando, Florida.

"The sustained improvement in GERD-HRQL scores and patient satisfaction, coupled with the potential for protection against esophageal cancer validate the long-term usefulness of this safe, clinically effective and economically effective endoscopic procedure," said principal investigator Mark Noar, M.D., Director, Endoscopic Microsurgery Associates, Maryland.  "Of the 99 study participants with refractory GERD followed for 10 years, 41 percent no longer required the PPI medications they were taking pre-Stretta."

Approximately 20 percent of Americans suffer the symptoms of GERD – frequent heartburn or acid reflux, burning sensation in the chest or throat or regurgitation – at least once a week, according to the National Institutes of Health.   

In some adults with GERD, atypical symptoms may present, such as dry cough, asthma, or trouble swallowing rather than, or in addition to heartburn.

Some 12 million Americans who do not respond to conservative GERD management – dietary changes or drug treatment – could potentially benefit from the Stretta procedure, including those with the atypical manifestations.

10-Year Post-Stretta Data Conclusions:  

  • Statistically significant and sustained improvement in GERD as measured by HQRL scores, patient satisfaction, and reduced medication requirements
  • Patients with variant anatomy and prior Nissen fundoplication (anti-reflux surgery) responded as well as those with normal anatomy
  • Demonstrable improvement in Barrett's tissue, and in some cases disappearance of metaplasia and dysplasia
  • The reduction in reflux as a result of the Stretta procedure may protect against esophageal cancer
  • The 10 year results compare favorably with the results of more invasive Nissen surgery, particularly when considering the substantially reduced risk of complications with Stretta versus all anti-reflux surgery methods

SAGES Gives Stretta Its Strongest Recommendation

The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) recently issued new Clinical Guidelines that give Stretta therapy for the treatment of GERD its highest recommendation based on strong clinical evidence from 32 clinical trials.

"This 10 year data adds to the already robust body of long term and Level 1 data for Stretta," said Will Rutan, CEO of Mederi Therapeutics. "This extremely long-term follow up confirms what was noted in the recent SAGES guidelines for GERD treatment…that Stretta is a very safe and very effective treatment whose time has come."

Stretta Reimbursement

Stretta is currently covered by Medicare in 12 states, nationwide by Tricare and the VA Systems, and locally by select commercial insurance carriers.  Together they insure more than 36 million Americans.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,912.11 -70.48 -0.42%
S&P 500 1,969.95 -8.96 -0.45%
NASDAQ 4,442.6980 -2.2110 -0.05%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs